8 NEWS
8 NEWS
11 OCTOBER 2024 ausdoc . com . au
Medical board fee ‘ extortionate ’
AAP Image |
Ciara Seccombe PROFESSOR Steve Robson says Medical Board of Australia fees are “ extortionate ” and “ unjustified ”, with doctors paying $ 1027 to renew their registration this year .
The fee has increased 3.2 % from last year .
Fees hitting four figures is symbolic , says the AMA ’ s immediate past president . “ You have got $ 3000
|
or $ 4000 in college fees , $ 50,000 a year for indemnity cover and now you have got over $ 1000 for AHPRA as the cherry on top .
“ We are starting to get into the $ 60,000- $ 70,000 range for doctors to practise .”
Professor Robson , an obstetrician , says politicians who are worried about media recriminations
|
have forced AHPRA to extend its remit into new areas .
But MPs should not
|
such as the crackdown on cosmetic surgery , he says .
“ While these projects were important , if health ministers want them , health ministers should invest in them .”
Other national boards have also raised their fees this year — in many cases by 4 % or slightly more .
But doctors will still pay hundreds of dollars more than any other profession to stay registered .
AHPRA CEO Martin Fletcher says he is “ acutely aware ” that health practitioners are dealing with a cost-of-living crisis but that fee increases are “ necessary to ensure we can continue our work and meet our regulatory obligations ”.
The $ 1027 fee does not apply to NSW doctors working under the state ’ s co-regulatory system , who will instead pay a $ 956 renewal fee .
|
|
|
Doctors should not be paying for ‘ fanciful projects ’. |
|
Professor Steve Robson . |
|
|
expect doctors to pay for “ fanciful projects ” unrelated to routine regulation , |
|
|
Visit repatha . com . au
for patient resources and information on how to prescribe Repatha ® on the PBS or privately
|
|
It ’ s now even easier to prevent another CV event with Repatha ® * 1 , 2
INITIATE NOW ON STREAMLINED AUTHORITY 3
* Repatha ® is indicated for the prevention of CV events ( MI , stroke and coronary revascularisation ) in adults with established CVD in combination with an optimally dosed statin and / or other lipid-lowering therapies , as an adjunct to diet and exercise . 1 ‘ Power ’: 15 % relative risk reduction with Repatha ® vs placebo in the composite of the primary endpoint beyond optimised statin ± ezetimibe ( HR : 0.85 ; 95 % CI : 0.79 – 0.92 , p < 0.001 ). 2
PBS Information : Authority required ( STREAMLINED ). Non-familial and familial hypercholesterolaemia . Criteria apply . Refer to PBS Schedule for full authority information .
Refer to full Product Information before prescribing ; available from Amgen Australia Pty Ltd , Ph : 1800 803 638 or by scanning the QR code :
For more information on Repatha ® or to report an adverse event or product complaint involving Repatha ® , please contact Amgen Medical Information on 1800 803 638 or visit www . amgenmedinfo . com . au .
* 1,2
Emeritus Professor John Murtagh AO
GP , educator and author of the specialty ’ s most influential textbook , John Murtagh ’ s General Practice .
CONGRATULATIONS to Australian Doctor on its 40th anniversary of bringing the publication to the medical profession . In particular , I would like to commend the team on its contribution to the education of GPs , especially through the regular reviews under the title of How to Treat and the clinical segments .
Precautions : Hypersensitivity reactions . Concomitant lipid-lowering therapies – check all relevant prescribing information . Immunogenic potential . Pregnancy Category : B1 . Caution – breastfeeding . Adverse Reactions : Common – nasopharyngitis , upper respiratory tract infection , influenza , back pain , arthralgia , nausea , rash , and injection site reactions ( including injection site pain , erythema , bruising , swelling or haemorrhage ).
Abbreviations : CI , confidence interval ; CV , cardiovascular ; CVD , cardiovascular disease ; HR , hazard ratio ; LDL-C , low-density lipoprotein cholesterol ; MI , myocardial infarction ; PBS , Pharmaceutical Benefits Scheme .
References : 1 . Repatha ® ( evolocumab ) Approved Product Information . 2 . Sabatine MS , et al . N Engl J Med . 2017 ; 376 ( 18 ): 1713 – 1722 . 3 . Pharmaceutical Benefits Scheme . Evolocumab . Available at : https :// www . pbs . gov . au / medicine / item / 10958R [ Accessed June 2024 ].
Amgen Australia Pty Ltd . ABN 31 051 057 428 , Sydney NSW 2000 . © 2024 Amgen Inc . All rights reserved . AUS-145-0624-80014 . AMG4138 . Date of preparation : June 2024 .
AMG4138 _ Repatha _ Streamlined Authority _ AusDoc _ A4 _ 210x273mmH _ OctNov _ R0.2 _ FA . indd 1 26 / 8 / 2024 6:17 PM